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Prevention of the initial infection of mucosal dendritic cells (DC) and interruption of the subsequent
transmission of HIV-1 from DC to T cells are likely to be important attributes of an effective human
immunodeficiency virus type 1 (HIV-1) vaccine. While anti-HIV-1 neutralizing antibodies have been difficult to
elicit by immunization, there are several human monoclonal antibodies (MAbs) that effectively neutralize virus
infection of activated T cells. We investigated the ability of three well-characterized neutralizing MAbs
(IgG1b12, 2F5, and 2G12) to block HIV-1 infection of human DC. DC were generated from CD141 blood cells
or obtained from cadaveric human skin. The MAbs prevented viral entry into purified DC and the ensuing
productive infection in DC/T-cell cultures. When DC were first pulsed with HIV-1, MAbs blocked the subse-
quent transmission to unstimulated CD31 T cells. Thus, neutralizing antibodies can block HIV-1 infection of
DC and the cell-to-cell transmission of virus from infected DC to T cells. These data suggest that neutralizing
antibodies could interrupt the initial events associated with mucosal transmission and regional spread of
HIV-1.
Dendritic cells (DC) at the mucosal surface of the genital
tract are likely to be the initial target of human immunodefi-
ciency type 1 (HIV-1) infection (19, 26, 33, 36). Intraepithelial
DC express CD4 and the beta chemokine receptor CCR5,
which serve as coreceptors for HIV-1 cell entry (46). During
their normal function of immunosurveillance, DC capture an-
tigen, traffic to draining lymph nodes, and present antigen to T
cells. During migration to regional lymph nodes, the maturing
DC upregulates expression of immunostimulatory molecules
such as B7.1 (CD80) and B7.2 (CD86). The mature DC then
presents antigen to T cells to initiate immunity (3, 8, 35, 37).
While the exact mechanism of mucosal transmission is un-
known, HIV-1 appears to exploit the normal DC pathway of
antigen uptake and presentation to gain access to the CD41 T
cells in the lymphoid tissue. In humans, active replication of
HIV-1 has been shown to occur in DC/T-cell syncytia at the
lymphoepithelial surface of tonsils (14), adenoids (14, 15), and
parotid glands and colon (13a). In macaques, intravaginal in-
oculation with the simian immunodeficiency virus appears to
target DC in the lamina propria of the cervicovaginal mucosa
(36), and in vitro studies have provided evidence for viral entry
into DC (1, 7, 17, 18, 28) and for viral replication in immature
DC (5, 43).
Immature DC selectively replicate macrophage-tropic iso-
lates of HIV-1 (16, 33, 46), while mature DC do not support
HIV-1 replication until they are cocultured with CD41 T cells
(1, 2, 7, 16, 17, 30–32, 44). In the mature DC/T-cell culture
system, robust HIV-1 replication occurs without mitogen stim-
ulation of T cells and without the addition of exogenous cyto-
kines (17, 32, 44). The DC/T-cell syncytia in these cocultures
are phenotypically similar to those observed in vivo (15, 30,
32). Recent studies have shown that freshly isolated (imma-
ture) epidermal Langerhans cells expressed CCR5 but not
CXCR4 on their surface and that these cells fused with CCR5
(R5) but not CXCR4 (X4) using HIV-1 envelopes (46). In
addition, when HIV-1 strains were applied to the abraded
epidermal surface of skin organ cultures, it was found that R5
viruses were selectively captured by DC that emigrated from
the explanted skin (33). These findings for cultured DC indi-
cate that DC may initiate HIV-1 transmission in vivo, by cap-
turing R5 HIV-1 and subsequently initiating viral replication in
T cells.
Neutralization of HIV-1 at the initial stages of virus entry
might be a critical determinant of vaccine efficacy. Most neu-
tralization studies have measured HIV-1 infection in mitogen-
and interleukin-2 (IL-2)-stimulated T cells (11), a target cell
type that may not participate in the initial events of infection.
It is not known if anti-HIV-1 antibody can prevent infection of
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mucosal DC or the subsequent transmission of HIV-1 from
DC to T cells. Since anti-HIV-1 antibodies that neutralize
infection by primary HIV-1 isolates are uncommon and are not
readily elicited by most HIV-1 immunogens (23), we studied
three human monoclonal antibodies (MAbs) (IgG1b12, 2F5,
and 2G12) that potently neutralize infection of activated T
cells by primary HIV-1 isolates (6, 21, 39). As a model for the
interaction of HIV-1 with DC at mucosal surfaces and in drain-
ing lymph nodes, we sought to determine if these MAbs could
prevent HIV-1 infection of pure DC as well as transmission of
HIV-1 from infected DC to unstimulated T cells. Using blood
and skin DC, we found that anti-HIV-1 neutralizing MAbs can
block both virus entry into DC and the transmission of HIV-1
from infected DCs to T cells. These data suggest that anti-
HIV-1 neutralizing antibodies could interrupt the mucosal
transmission and regional spread of HIV-1 and that a vaccine
eliciting neutralizing antibody could prevent mucosal transmis-
sion of HIV-1.
MATERIALS AND METHODS
Preparation of blood DC. DC were generated from the blood of normal
donors by using protocols similar to those previously reported (4, 34). Peripheral
blood mononuclear cells (PBMC) obtained by Ficoll-Hypaque sedimentation
were depleted of CD31 T cells by two incubations with anti-CD3 immunomag-
netic beads (Dynal Inc., Great Neck, N.Y.). The T-cell-depleted leukocytes were
adhered to immunoglobulin G (IgG)-coated plastic flasks, and nonadherent cells
were vigorously removed by four washes with phosphate-buffered saline. Adher-
ent cells were maintained for 7 days in culture medium (RPMI 1640 medium
supplemented with 15% heat-inactivated fetal calf serum, 100 U of penicillin per
ml, 100 mg of streptomycin per ml, and 2 mM L-glutamine) containing 1,000 U
each of recombinant human IL-4 (R&D Systems, Minneapolis, Minn.) and
granulocyte-macrophage colony-stimulating factor (Immunex, Seattle, Wash.)
per ml. Cytokines were replenished on alternate days. On day 7, culture medium
was replaced with macrophage conditioned medium (MCM) that was also sup-
plemented with 1,000 U each of granulocyte-macrophage colony-stimulating
factor and IL-4 per ml. To prepare MCM, PBMC were adhered to IgG-coated
plastic flasks in culture medium containing 10% heat-inactivated normal human
serum. After removal of nonadherent cells, the MCM supernatant was collected
daily for 5 days. Cell-free supernatant was analyzed for the level of tumor
necrosis factor alpha by enzyme-linked immunosorbent assay (R&D Systems),
and medium containing 50 IU or more was used as MCM. Mature DC were
harvested for use on day 11 and resuspended in culture medium without sup-
plemental cytokines. Purified CD31 T cells were obtained by positive selection
from PBMC as described above, using anti-CD3 immunomagnetic beads accord-
ing to manufacturer’s instructions. Viability of cryopreserved purified CD31 T
cells was routinely $90%; the cells did not proliferate when returned to culture.
Skin-derived DC. Skin-derived DC and T cells were obtained from split-
thickness skin harvested from cadavers within 12 h of death (Lifenet, Virginia
Beach, Va.) as previously described (29–31). Briefly, skin explants were placed
dermal side down in 150-ml tissue culture dishes (Corning Plastics, Corning,
N.Y.) in 45 ml of culture medium. The skin was cultured for 2 to 4 days, and the
migrated cells were treated with collagenase D (Boehringer Mannheim), washed,
and resuspended in culture medium. Skin leukocytes from this organ culture
method contain a mixture of DC and CD31 T cells and are permissive for HIV-1
replication (29, 30, 32). To obtain pure skin DC, skin leukocytes were depleted
of CD31 T cells by using anti-CD3-coated immunomagnetic beads as described
above.
Flow cytometry. DC were characterized by two-color staining with fluorescein
isothiocyanate- and phycoerythrin-conjugated mouse MAbs, using a FACScan
flow cytometer (Becton Dickinson, San Jose, Calif.). The MAbs used were
anti-HLA-DR, anti-CD80, anti-CD86, anti-CD3, anti-CD14, anti-CD19, and
anti-CD45 (Becton Dickinson); anti-CD83 (Immunotech, Miami, Fla.); and anti-
CD1a (PharMingen, San Diego, Calif.) and isotype-matched controls. CD45-
negative events were excluded from the fluorescence-activated cell sorting anal-
ysis.
Immunohistochemical staining of cytospin preparations. Cell cytospins were
prepared as previously described (14, 31, 32). The primary antibodies were
anti-HLA-DR, anti-CD3, anti-CD4, anti-CD8, anti-CD20, anti-CD68, anti-S-
100, and anti-HIV-1 p24gag (DAKO, Carpinteria, Calif.) and anti-CD1a, anti-
CD80, and anti-CD83 (Immunotech). Cytospins of infected DC/T-cell cultures
were prepared between 2 and 11 days after exposure to HIV-1.
Virus stocks. HIV-1 isolates BaL, 89.6, and IIIB were obtained from the NIH
AIDS Reference and Reagent Repository, and isolates US1 and SG365 were
from the repository of the U.S. Military HIV Research Program. Virus stocks
were prepared by infection of phytohemagglutinin (PHA)-stimulated PBMC as
previously described (22). BaL, US1, and SG365 are primary R5 viruses. HIV-1
89.6 is known to use both CCR5 and CXCR4 (10), and IIIB is a T-cell line-
adapted (TCLA) virus (12). BaL, US1, and IIIB have been previously charac-
terized as genetic subtype B, and SG365 has been characterized as genetic
subtype C (20). SG365 is resistant to neutralization by the MAbs that we tested
(unpublished data).
Antibodies. Anti-HIV-1 human MAbs IgG1b12, 2F5, and 2G12 were chosen
because each can block infection of PHA-stimulated PBMC target cells by
primary isolates of HIV-1 (6, 39, 40). MAb 2F5 recognizes the gp41 sequence
ELDKWA (9, 27); MAbs 2G12 and IgG1b12 bind to different conformationally
sensitive epitopes on gp120 (6, 40). A control nonneutralizing MAb (4.8D) was
obtained from the NIH AIDS Reference and Reagent Repository (donated by
James Robinson). MAb 4.8D binds to a conformational epitope on gp120 but
does not neutralize primary HIV-1 isolates at concentrations of up to 50 mg/ml
(11). All four MAbs are isotype IgG1.
DC infection and antibody neutralization assays. Virus infection and neutral-
izing antibody experiments with DC were performed by using methodologies
similar to those previously described for PHA/IL-2-stimulated PBMC (21, 22).
Blood DC harvested on day 11 were washed, resuspended in culture medium,
and exposed to 500 50% tissue culture infectious doses (TCID50) of virus per 5 3
104 cells (multiplicity of infection [MOI] 5 0.01) in triplicate wells. DC were
exposed to virus overnight, or for 90 min as noted, and then washed. For
neutralization experiments, virus and antibody were preincubated for 30 min at
37°C prior to the addition of DC. Since mature DC replicate HIV-1 only in the
presence of T cells, positively selected CD31 cells were added back to the DC
(2:1 ratio of CD31 cells to DC). Virus replication was monitored by enzyme-
linked immunosorbent assay measurement of p24 antigen produced in culture
supernatants. Neutralization was assessed at days 6 to 8 for DC/T cells, or days
4 to 6 for PHA/IL-2-stimulated PBMC, representing the early kinetics of virus
growth. Neutralization experiments with skin DC (depleted of CD31 T cells)
were performed in a similar manner.
Molecular detection of viral entry and proviral formation. A semiquantitative
PCR measurement of early and late HIV-1 reverse transcripts in cell lysates was
used to assess viral entry and proviral formation, respectively, based on a mod-
ification of published techniques (17, 45). Briefly, viral supernatant was centri-
fuged at 900 3 g for 10 min, filtered through a 0.22-mm-pore-size filter, and
treated with RNase-free DNase (50 U/ml; Boehringer Mannheim Corp., India-
napolis, Ind.). DC were exposed to virus (MOI 5 0.01) for 90 min at 37°C,
washed to remove unabsorbed virus, and then cultured alone or with CD31 T
cells. Cell lysates from approximately 25,000 cells were separately amplified with
32P-end-labeled sense oligonucleotides to generate 108- and 204-bp products
representing early and late viral reverse transcripts, respectively. Equivalent
amounts of lysate were subjected to amplification with 32P-end-labeled primers
specific for the single-copy gene CCR5 (25). PCR products were resolved on 8%
nondenaturing polyacrylamide gels and quantitated by using storage phosphor
technology. Copy numbers were computed by comparison to a calibrated series
of ACH-2 cell lysates which contain a single provirus per cell (13) and then
normalized for cell input by reference to CCR5 signal intensity.
RESULTS
Purified mature DC do not become productively infected
with HIV-1 but can transmit HIV-1 to unstimulated T lym-
phocytes. We generated mature blood DC from adherent
CD141 PBMC. Since our methods were slightly different than
those described (4, 34), we reconfirmed that mixtures of ma-
ture DC and T cells, but not pure DC or T cells alone, are
permissive for HIV-1 replication (17, 30–32). After culture in
cytokines, the DC developed into a uniform population of
large cells with typical processes, with both veils and dendrites.
They maintained this morphology despite the withdrawal of
exogenous cytokines on day 11. The population was homoge-
neous by cytofluorometry and by immunocytochemical stains
on cytospins. Less than 1% of the cells expressed CD14, CD19,
CD56, or CD3. The cells expressed high levels of HLA-DR,
the immunostimulatory molecules CD80 and CD86, and the
DC marker CD83. Functionally, the DC were potent stimula-
tors of an allogeneic mixed leukocyte response, inducing strong
lymphoproliferative responses with 100- to 1,000-fold-fewer
cells than PBMC stimulators (data not shown). Thus, these DC
fulfill the phenotypic and functional criteria for mature DC
(35). When exposed to HIV-1 BaL, neither mature DC alone
nor CD31 T cells alone became productively infected. How-
ever, robust HIV-1 replication was observed if CD31 T cells
were added to DC that had been pulsed with HIV-1 and
washed (Fig. 1).
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Neutralizing MAbs inhibit productive infection of DC/T-cell
cocultures. Preliminary data showed that HIV-1 BaL infection
of PBMC targets was abrogated (95 to 99% neutralization) by
MAb IgG1b12 (25 to 50 mg/ml) or by the combination of MAbs
2G12 and 2F5 (each at 25 mg/ml). MAbs 2F5 and 2G12 were
less potent individually than in combination. Thus, MAb
IgG1b12 and the combination 2F5/2G12 were used for DC
neutralization experiments. The neutralization dose-effect
curves for IgG1b12, 2F5/2G12, and the nonneutralizing MAb
4.8D, using PBMC or DC targets, are shown in Fig. 2A and B,
respectively. No productive infection was seen in DC/T-cell
cultures when MAbs IgG1b12 and 2F5/2G12 were preincu-
bated with BaL at concentrations of .10 mg/ml. These exper-
iments were repeated several times with similar results. The 90
and 99% inhibitory concentrations for MAbs were approxi-
mately 5- to 10-fold lower when DC were use as targets than
when activated PBMC were used. Antibody-mediated virus
neutralization in DC/T-cell cultures was confirmed by immu-
nocytochemical analysis of cultured cells. The p24 antigen
found almost entirely in small and large syncytia in the cultures
was uniformly absent in cytospins of DC/T-cell cultures when
BaL had been preincubated with MAb IgG1b12 (Fig. 2C).
To evaluate neutralization of other HIV-1 strains, experi-
ments were performed with the TCLA virus IIIB, the dual-
tropic strain 89.6, and a primary R5 isolate, US1. With the
MAb combination 2F5/2G12, greater than 99% neutralization
of all four viruses was seen, although infection of DC by US1
was not completely prevented. As a control for possible non-
specific MAb effects on cell growth, we used a clade C virus
(SG365) previously shown to be insensitive to neutralization by
2F5/2G12. SG365 infection of DC/T-cell cultures was not neu-
tralized by 2F5/2G12 (Fig. 3).
Neutralizing MAbs block entry of HIV-1 into DC. To deter-
mine if neutralizing MAbs block entry of HIV-1 into DC, we
FIG. 1. Infection kinetics of purified DC cultured in the presence and ab-
sence of T cells. The DC were exposed to HIV-1 BaL (500 TCID50/105 DC)
overnight at 37°C, thoroughly washed to remove free virus, and cultured alone or
with positively selected CD31 T cells. PHA/IL-2-stimulated PBMC and unstimu-
lated CD31 cells were infected in a similar manner. No p24 antigen expression
was detected in purified DC or CD31 T cells alone. Robust infection, close to
that seen with activated PBMC, was detected when T cells were added to
infected DC. During infection, DC and CD31 cells were cultured in medium
without exogenous cytokines. PBMC were maintained in culture medium sup-
plemented with 20 U of IL-2 per ml.
FIG. 2. (A and B) Antibody-mediated neutralization of HIV-1 BaL infection of PHA/IL-2 stimulated PBMC (A) and DC (B), with CD31 cells added on day 1 after
exposure of DC to HIV-1. MAb IgG1b12, or the combination 2F5/2G12, was preincubated with virus at a starting concentration (for each MAb) of 50 mg/ml prior to
addition of PBMC or DC. Extracellular p24 antigen was measured in the early viral growth phase for PBMC (day 4) and DC/T cells (day 7). Identical concentrations
of the nonneutralizing MAb 4.8D did not inhibit viral infection of PBMC or DC targets. (C) Immunocytochemical staining of DC/T-cell cytospins for p24 antigen
expression (brown) and HLA-DR (purple). The right-hand panel shows a p24-positive syncytium on day 7 after DC exposure to BaL (magnification, 3200). No
HIV-1-infected cells were seen when BaL was preincubated with 25 mg of MAb IgG1b12 per ml (left, p24 antigen stain only; 3160).
FIG. 3. Neutralization of four clade B HIV-1 isolates by the combination
2F5/2G12 (each at 25 mg/ml). Target cells were DC with T cells added back as in
Fig. 1. Stippled bars indicate preincubation of DC with MAbs; gray bars show
virus growth without antibody. The clade C isolate (SG365) was not neutralized
by 2F5/2G12.
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quantitated early and late HIV-1 reverse transcripts present in
cell lysates by PCR. As shown in Fig. 4, HIV-1 BaL was incu-
bated with DC or PBMC, and early and late transcripts were
amplified at 0, 6, 36, and 96 h after infection. Similar to find-
ings in a previous report (17), only early transcripts were de-
tected in pure cultures of mature DC, whereas both early and
late reverse transcripts were detected in DC/T-cell cultures and
activated PBMC. Preincubation of BaL with the MAb combi-
nation 2F5/2G12 (each at 25 mg/ml) blocked the formation of
early reverse transcripts in pure DC (Fig. 4A). The weak or
undetectable early transcript signal at 6 and 36 h after DC
infection indicates the lack of effective viral entry. As expected,
2F5/2G12 also blocked the formation of late transcripts in
DC/T-cell and PBMC cultures. In a separate experiment, sim-
ilar data were obtained with MAb IgG1b12 (25 mg/ml) used in
place of 2F5/2G12 (data not shown).
Neutralizing MAbs block transmission of HIV-1 from in-
fected DC to unstimulated T cells. It might be difficult for
immunization to elicit an effective concentration of neutraliz-
ing antibody at mucosal surfaces where HIV-1 first interacts
with DC. Thus, we sought to determine if neutralizing MAbs
could interfere with transmission of HIV-1 from infected DC
to unstimulated T cells, an event which may be relevant to the
initial transmission of HIV-1 in draining lymph nodes. Blood
or skin DC were pulsed with HIV-1 BaL for 90 min at 37°C,
extensively washed, and returned to culture. MAb was added
to the culture 24 h later, and T cells were added 30 min after
antibody. On blood DC (Fig. 5A), MAb IgG1b12 blocked the
transmission of BaL from purified, infected DC (which con-
tained early reverse transcripts) to T cells. In the absence of
neutralizing antibody, these same DC established a vigorous
infection when combined with T cells. When T cells were
obtained from a donor homozygous for the 32-bp deletion in
the CCR5 gene, a coreceptor defect known to abrogate infec-
tion with CCR5-using HIV-1 strains, there was no propagation
of HIV-1 infection. This finding demonstrates that transmis-
sion of infection from DC to T cells was CCR5 dependent.
Prior work has shown that functional CCR5 is needed on both
DC and T cells to obtain a productive HIV-1 infection with R5
viruses (16). To test the ability of MAbs to prevent HIV-1
transmission from skin DC to T cells, we used skin DC de-
pleted of CD31 cells. Similar to results of experiments with
blood DC, pure skin DC replicated virus only upon addition of
CD31 cells to the culture (Fig. 5B). Neutralizing MAbs com-
pletely blocked transmission of HIV-1 infection to T cells by
skin DC that had been pulsed with HIV-1.
DISCUSSION
The protective mechanisms of immunoglobulin at mucosal
surfaces are likely to be complex. Both locally produced IgG
and IgA and transudative IgG could play a role in protective
immunity (24). In this study, we used IgG MAbs along with
blood and skin DC to model the interaction of antibody,
FIG. 4. Neutralizing MAbs block virus entry into DC. Purified blood DC were exposed to a DNase-treated, cell-free virus stock (HIV-1 BaL; MOI 5 0.01) in the
presence or absence of MAb combination 2F5/2G12 (each at 25 mg/ml) and subsequently incubated alone (DC) or in the presence of purified CD31 T cells (DC/TC).
Parallel control infections of PHA/IL-2-stimulated PBMC were also conducted. Cell lysates were prepared at the times indicated postinfection and amplified with
32P-labeled primers specific for early and late HIV-1 reverse transcripts and for CCR5. Parallel amplification of known numbers of ACH-2 cells (which contain a single
integrated HIV-1 provirus per cell) were performed with each primer set to provide a copy number quantitation curve. (A) Early reverse transcripts (RU5 long terminal
repeat [LTR] region sequences). (B) Late reverse transcripts (LTR/gag). Arrows indicate the positions of specific signals; the remaining visible bands are nonspecific
(i.e., no late reverse transcripts were seen in PBMC until the 36-h time point). (C) CCR5 gene amplification (cell number control).
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HIV-1, and DC at mucosal surfaces and in lymphoid tissue.
Three HIV-1 envelope-specific human IgG MAbs were studied
because they were previously shown to neutralize HIV-1 in-
fection of activated T cells. Our data show that these MAbs
prevent HIV-1 infection of pure DC and block the transmis-
sion of HIV-1 from infected DC to unstimulated T cells. Neu-
tralization dose-response data demonstrated potent antibody-
mediated virus neutralization when pure DC were used as
targets of infection. MAb concentrations of $10 mg/ml re-
sulted in complete neutralization of virus infection in the DC
cultures. The reason that inhibition of HIV-1 infection of DC
occurred at antibody concentrations lower than required to
block infection of mitogen-stimulated T cells is not clear. Ad-
ditional experiments are in progress to carefully monitor rep-
lication kinetics in each culture system, using virus titered on
each target cell (47). When DC were exposed to HIV-1 in the
presence of neutralizing MAb, immunocytochemical staining
of DC/T-cell cultures showed no p24-positive DC/T-cell syn-
cytia. In comparison, and as previously described (30–32), mul-
tiple DC/T-cell syncytia were seen on cytospins from cultures
of DC exposed to HIV-1 in the absence of MAb. We also
tested the neutralizing activity of MAbs against HIV-1 strains
other than HIV-1 BaL. Potent neutralization was demon-
strated for a TCLA strain, a dualtropic (R5 and X4) virus, and
a clinical R5 isolate (IIIB, 89.6, and US1, respectively). Thus,
these MAbs appear to show broad anti-HIV neutralizing ac-
tivity on DC targets, as they do on PBMC targets. Prior studies
have shown that HIV-1 efficiently enters mature DC, but only
early products of reverse transcription are produced until T
cells are added to the culture (16, 17). We confirm these data
and show that neutralizing MAbs block viral entry, as assessed
by the absence of early reverse transcripts in pure DC cultures.
While our initial experiments focused on the ability of anti-
body to block virus entry into purified DC, it may be more
relevant to mucosal HIV-1 infection to determine if antibody
can block transmission of HIV-1 from an infected DC to a
resting T cell. We modeled this interaction by treating HIV-
1-pulsed DC with MAb prior to the addition of unstimulated T
cells and observed no virus replication. Results were similar for
blood-derived and skin DC. These data suggest that if luminal
antibodies fail to prevent the initial interaction of HIV-1 with
DC, antibodies present at draining lymph nodes could inter-
rupt DC-to-T-cell transmission. Several groups have studied
the mechanism of DC-to-T-cell HIV-1 transmission (5, 16, 17,
41, 44). Granelli-Piperno and colleagues recently showed that
functional CCR5 on both DC and T cells was required for DC
to infect T cells (16), and Weissman et al. reported that trans-
mission from HIV-1-pulsed DC to T cells could be blocked by
anti-CD4 antibody (44). Our data confirm that transmission to
T cells is dependent on CCR5 and are the first to show that
HIV-1 transmission to DC can be blocked by HIV-1 envelope-
specific antibody. Taken together, these results suggest that
neutralizing MAbs are blocking DC-to-T-cell transmission via
established mechanisms, i.e., by blocking virus binding to CD4
or CCR5 or by inhibiting gp41-mediated cell fusion (38, 42).
Our results are limited to IgG HIV-1 envelope-specific MAbs
and do not address the role of IgA at mucosal surfaces (24).
In summary, our data demonstrate that anti-HIV-1 neutral-
izing antibodies block HIV-1 entry into DC, the likely first cells
infected at the mucosal surface. In addition, neutralizing anti-
bodies block the in vitro transmission from HIV-1-infected DC
to unstimulated T cells, indicating that antibody could inter-
rupt the initial spread of HIV-1 in draining lymph nodes.
These data suggest that both mucosal and systemic immuno-
globulin could play a role in prevention of sexual transmission
of HIV-1, thus supporting the rationale that generation of a
neutralizing antibody response will be an important compo-
nent of an effective HIV-1 vaccine.
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